Cortechs.ai | Cortechs.ai receives US FDA Clearance for quantitative brain image analysis

Cortechs.ai receives US FDA Clearance for quantitative brain image analysis

Renewed FDA 510(k) clearance for NeuroQuant advances the field of quantitative imaging to support neurological professionals in their clinical decision making.

(San Diego, CA) September 19, 2017 – Cortechs.ai, the leading medical software innovator providing solutions for quantitative brain volume analysis, is pleased to announce that it has received 510(k) clearance from the U.S. Food & Drug Administration (FDA) for NeuroQuant®.

Previously cleared for automatic labeling and volumetric quantification of segmentable brain structures from MRIs, this latest clearance unveils updated and advanced NeuroQuant features for the US market.

“This latest US FDA 510(k) clearance is a continued testament to our commitment to quality and performance of NeuroQuant,” said Guri Stark, Cortechs.ai’ CEO. “Cortechs.ai’ outstanding engineering team has developed a robust and sophisticated quantitative image analysis software above what is currently available in the market. We are excited to provide the next level of quantitative brain volume analysis software to assist physicians and researchers in their assessment of neurological conditions via MR imaging.”

NeuroQuant features and benefits:

  • Fast, accurate and automated quantitative MR image analysis
  • Proven and consistent brain structure segmentation and volume measurement
  • Dynamic Atlas™ provides personalized brain segmentation driven by advanced precision
  • Normative reference data, available for ages 3 years to 100, compares patient brain volumes to healthy cohorts based on age and gender
  • Volumetric reports provide physicians with supplemental information for the assessment of neurological conditions
  • LesionQuant module provides quantitative analysis of FLAIR lesion volumes and brain structures
  • Compatible with Siemens, GE, Philips, and Toshiba (1.5T and 3.0T) and Hitachi (1.2T, 1.5T and 3.0T)
  • Longitudinal tracking to evaluate brain structure volumes over time

About Cortechs.ai

Cortechs.ai develops and markets breakthrough medical device software solutions capable of automatically segmenting and quantifying brain structures, making quantitative analysis of the human brain a routine part of clinical practice. Cortechs.ai’ cutting-edge brain imaging analysis provides neurologists, radiologists, and clinical researchers worldwide with a convenient and cost-effective means to quantify subcortical structures to help assess a variety of neurological conditions, such as Alzheimer’s disease, epilepsy, multiple sclerosis, brain trauma and brain development. Please visit cortechs.ai for further information.

###

Media Contact
Travis Foegler
Phone: +1 (619) 450-9094
Email: [email protected]

More Resources

08/18/2025

Why Bigger Normative Databases Mean Better Brain Imaging

NeuroQuant® 5.2 compares patient brain MRI volumes to over 7,000 healthy scans, giving clinicians clear, percentile-based context for better assessments.

08/07/2025

Navigating Reimbursement for NeuroQuant: Understanding CPT Codes 0865T & 0866T 

Let’s break down the latest category III CPT codes and example clinical use cases that illustrate their value.

07/31/2025

Precision Without the Pressure: Smarter Brain Tumor Monitoring

Learn about NeuroQuant Brain Tumor 2.0 and how it assists clinicians by providing objective quantification and analysis of tumor changes over time.

07/30/2025

Cortechs.ai Announce Next-Gen NeuroQuant Brain Tumor: AI-Driven Metastasis & Meningioma Segmentation 

NeuroQuant Brain Tumor is the first FDA-cleared, cloud-native tool to offer automated volumetric segmentation for brain metastases, meningiomas, and gliomas.

07/28/2025

Longitudinal Assessment of Traumatic Brain Injury Using NeuroQuant®

A case study with Dr. Suzie Bash on NeuroQuant as a reliable, reimbursable, and efficient tool in the evaluation and follow-up of TBI.

07/24/2025

Understanding the Hippocampal Occupancy Score

One of the most frequently asked questions among customers is, “What does the Hippocampal Occupancy Score (HOC) represent within the Dementia Report?”
Scroll to Top